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Background
Coronary heart disease (CHD) is a leading cause of morbidity and mortality in chronic kidney disease (CKD). Individuals with CKD are at greater risk for major adverse cardiac events (MACE) than the general population (1) . Despite this, traditional risk factor reduction strategies that reduce MACE in the general population such as lowdensity lipoprotein cholesterol (LDL-C) lowering confer less benefit in CKD patients (2) .
In the Study of Heart and Renal Protection (SHARP), although treatment with simvastatin plus ezetimibe in subjects with CKD led to a 17% reduction in a composite cardiovascular outcome compared to placebo, it did not reduce all-cause or CHD mortality (3) .
Low levels of high-density lipoprotein cholesterol (HDL-C) and high triglyceride (TG) levels are both associated with CKD (4). Niacin raises HDL-C and lowers TG levels.
However, it is not known whether raising HDL-C and lowering TG translates into improved cardiac outcomes in CKD patients.
Prior studies suggest that lipid lowering therapy may also prevent progression of CKD (5) . While animal studies suggest that niacin may protect against GFR loss, (6) to our knowledge, the effect of ERN on longitudinal change in kidney function in humans has not been studied previously. The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) tested the hypothesis that ERN, when added to intensive statin therapy reduced MACE in stable CHD patients pre-selected for low baseline HDL-C and elevated triglycerides (TG) as compared with placebo. Ezetimibe could be added to either arm, as needed, to achieve and maintain an on-treatment LDL-C between 40-80 mg/dL. The primary outcome study findings from AIM-HIGH did not show incremental clinical benefit of ERN versus placebo on MACE when added to optimal LDL-C reduction therapy despite a significant improvement in the lipid profile (7) .
The present investigation was a post hoc analysis of participants with CKD enrolled in the AIM-HIGH trial. Because the CKD population represents a subset with high cardiac risk, we hypothesized that raising HDL-C and lowering TG with ERN would improve cardiovascular outcomes in these subjects. Secondary objectives were to evaluate the effect of ERN on longitudinal change in kidney function as well as safety and tolerability in participants with CKD. 
Results
Baseline characteristics: Of the 3,413 participants with non-missing eGFR in the AIM-HIGH trial, 85.2% were male, 3.4% African Americans, and 4.1% were of Hispanic ethnicity. Five hundred and five study participants (14.8%) had CKD at baseline. Among these, the mean eGFR was 50.3 ± 7.7 ml/min per 1.73m². 496 participants (98.2%) had an eGFR within the range of 30-59 mL/min per 1.73m², and 9 (1.8%) had an eGFR < 30 mL/min per 1.73m².
Approximately 80% of the CKD participants were male, 4 % African Americans, and 3.4% were Hispanics. Compared to participants without CKD, those with CKD were older and more likely to be female, had higher prevalence of diabetes and hypertension, but were less likely to use tobacco. Systolic blood pressures and pulse pressures were slightly higher in CKD participants (Table 1) .
Among participants with CKD randomized to ERN (n=254) or placebo (n=251), demographic variables, medical conditions, and CAD risk factors were balanced between treatment arms. Lipid profiles in CKD subjects randomized to placebo or ERN were also similar at baseline ( Table 2) .
Effect of ERN on lipids in CKD:
Participants from both CKD and non-CKD groups achieved significant increases in HDL-C and decreases in TG concentrations in the ERN arm relative to placebo. In the CKD group, baseline HDL-C concentration was 34.5 mg/dL and 34.9 mg/dL for the placebo and ERN groups respectively. At 3 years, mean HDL-C concentrations were 39.2 (8.2) mg/ dL and 45.9 (12.6) mg/dL, respectively (placebo vs ERN, P<0.0001). In the CKD group, median (IQR) baseline TG 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 endpoints,in models with/without eGFR stratification (data not shown). Most of the noncardiovascular deaths were due to cancer (Table 4) .
Longitudinal Change in Kidney Function:
When the entire study sample was evaluated together regardless of CKD status, there was a mean decrease in eGFR of 2.8% (14.0%) in those randomized to placebo (n= 872) and a 1.2% (14.8%) decrease in those treated with ERN (n = 866) over 3 years (p=0.03). There was statistically Table 5 . In participants with CKD, there was a 3.3% (24.2%) improvement in eGFR from baseline to year 3 in those randomized to placebo, whereas there was a 1.8% (22.3%) decrease in those randomized to ERN, a result that did not reach statistical significance (p=.10). Conversely, in the subset without CKD, there was a 3.8% (13.6%) decrease in eGFR in those randomized to placebo, whereas those randomized to ERN experienced only a 1.1% (13.5%) decrease in eGFR over 3 years ( Figure 1 ). This finding was statistically significant (p=0.0001). No new incident cases of CKD were observed during the study.
Adverse Events and Treatment Discontinuation:
Within the CKD group, there was a significantly higher rate of discontinuation of ERN compared to placebo (32.7% vs.
22.7%, p = 0.01). In the ERN arm, higher rates of flushing, increased glucose, and gastrointestinal symptoms were observed compared to the placebo arm. Specifically for symptomatic flushing/itching, these symptoms accounted for near 30% of the primary reason for drug discontinuation in the ERN arm compared to 14% in the placebo arm in the CKD group (Table 6 ). 
Discussion
In this secondary analysis from AIM-HIGH, there was no incremental benefit of adding ERN to simvastatin-versus placebo in the important, high-risk subset of CKD patients with respect to secondary prevention of cardiovascular events. As expected, the CKD patients had a much higher primary end-point than the non-CKD group indicating a very high residual CVD risk in this subgroup. It is also important to note that most of the noncardiovascular deaths were due to cancer, but no association between niacin treatment and cancer was observed. From the early stages of CKD, abnormal apolipoprotein metabolism can be demonstrated (9). Oxidative stress is part of the complex interplay between CKD and heart disease (10), and is linked to endothelial dysfunction (11), that is highly prevalent in patients with moderate to severe CKD (12, 13) . Patients with CKD are at high risk for shown to be cardio protective in non-dialytic CKD patients (16, 17) . These results suggest that LDL plays a more important role than HDL-C in cardiovascular disease in CKD, and that there may be a role for TG although we could not demonstrate in our study. Studies testing inhibition of cholesteryl ester transfer protein (CETP) such as torcetrapib and dalcetrapib failed to demonstrate improvement in cardiovascular outcomes despite successfully increasing HDL-C levels (18, 19) . The recently completed HPS-2 THRIVE (Second Heart Protection Study Treatment of HDL to Reduce Incidence of Vascular Events) study is the largest prospective randomized trial testing niacin in patients at high-risk for CV events to date, and failed to demonstrate cardioprotective effects (20) .
Another important endpoint of this study was to examine the effects of ERN on longitudinal change in kidney function and to assess the tolerability in CKD patients. We observed a slower rate of decline in eGFR in ERN treated patients when all AIM-HIGH participants were examined together. In non-CKD patients, ERN therapy was also associated with a slower rate of eGFR decline than placebo. These data indicate that 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 There is a major need in conducting prospective randomized trials in patients with early stages of CKD in order to improve cardiovascular outcomes. In fact, the new KDIGO (Kidney Disease improving Global Outcomes) report persuasively argues for more research on the treatment of dyslipidemias in patients with CKD who have either elevated levels of TG or low levels of HDL-C (24). Although AIM-HIGH is one of the largest prospective studies evaluating the use of combined statin-ERN treatment for secondary cardiovascular prevention that included a sizeable proportion of patients with CKD, the sample size and number of deaths were relatively small. These factors limit inferences on differences and causes of mortality we can draw from this study. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 In summary, in CKD patients with atherogenic dyslipidemia from AIM-HIGH treated with ERN conferred no significant benefit on cardiovascular events despite significant increases in HDL-C and reduction of TG. Renal function decline was significantly slowed in AIM-HIGH patients as a whole, but no significant cardiovascular benefit was seen in the CKD sub-group. These findings coupled with a similar lack of cardioprotective benefits in the overall AIM-HIGH trial and in the much larger HPS2-THRIVE trial, raise doubts regarding the utility of this treatment strategy in the statin era. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Methods

Study Design
The AIM-HIGH study design and baseline characteristics of the study population have been described in detail previously (7, 25) . Briefly, AIM-HIGH was a multi-center, prospective, randomized, double-blind, placebo-controlled trial in men or women age 45 years or older with established, stable cardiovascular disease and atherogenic dyslipidemia defined as low baseline HDL-C (< 40 mg/dL for men and < 50 mg/dL for women), high TG (100 -400 mg/dL) and LDL-C < 180 mg/dL (adjusted for statin treatment at entry). Participants were recruited from 92 centers in the United States and Canada. The hypothesis was that raising HDL-C (as well as lowering TG, LDL-c, and lipoprotein a with extended-release niacin (ERN, Niaspan™, AbbVie Inc.) would decrease the rate of a composite primary endpoint (coronary artery disease mortality, non-fatal myocardial infarction, ischemic stroke, hospitalization for acute coronary syndrome or symptom-driven coronary or cerebral revascularization), during a projected mean 55 month follow-up. Participants with serum creatinine ≥ 2.5 mg/dL at screening were excluded. During a 4 -8 week open label run-in period, all patients were treated with 40 mg of simvastatin and doses of ERN increasing weekly from 500 mg/day to 2,000 mg/day. Patients tolerating at least 1,500 mg/day of ERN were randomly assigned to ERN or placebo. The placebo tablets contained a small dose (50 mg) of immediate-release niacin in each 500-mg or 1000-mg tablet to mask the identity of the blinded treatment to patients and study personnel. All participants were treated with simvastatin (20-80 mg daily) with dose adjusted as needed to achieve a target LDL-C of reviewed by an independent clinical events adjudication committee, masked to the identity of treatment. Primary endpoints for this post-hoc analysis were identical to the study proper, as noted above. In addition, we compared annual changes in estimated GFR (eGFR) and incident CKD rates between treatment arms and by kidney function group. CKD was defined as estimated GFR of < 60 mL/min/1.73 m². Study participants that were not classified as CKD at baseline but had an eGFR < 60 mL/min/1.73 m² at the end of the study were counted as incident CKD cases. Study participants were evaluated for adverse effects in clinic or by phone on a quarterly basis. We compared rates of serious adverse events and drop-out rates by treatment arm and by kidney function group.
Page 14 of 27
The International Society of Nephrology (http://www.isn-online.org/site/cms) Kidney International   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 This study was funded by the National Heart, Lung, and Blood Institute (HL 081649 and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 F o r P e e r R e v i e w O n l y Change from baseline -0.7 (-9.4, 5. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47 F o r P e e r R e v i e w O n l y 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48 
